Evidence map›Paper›PMID 39331092›Full record

ArticleCancer biomarkers : section A of Disease markers2024

Blood endocan as a biomarker for breast cancer recurrence.

Kentaro Daiki, Yoko Kanada, Aya Nagata, Kanae Taruno, Katsuhide Igarashi, Toshiko Yamochi, Hirotaka Ota, Fumiaki Sato, Seigo Nakamura, Yoshinori Kato

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kentaro DaikiLaboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Yoko KanadaDepartment of Breast Surgical Oncology, Tokyo Rosai Hospital, Tokyo, Japan.
Aya NagataDepartment of Breast Surgical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
Kanae TarunoInstitute for Clinical Genetics and Genomics, Showa University, Tokyo, Japan.
Katsuhide IgarashiLaboratory of Biofunctional Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Toshiko YamochiDepartment of Pathology, Showa University School of Medicine, Tokyo, Japan.
Hirotaka OtaDepartment of Pathology, Showa University School of Medicine, Tokyo, Japan.
Fumiaki SatoLaboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Seigo NakamuraInstitute for Clinical Genetics and Genomics, Showa University, Tokyo, Japan.
Yoshinori KatoLaboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.

objectiveThis study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.

methodsBlood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).

resultsOur preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.

conclusionsOur results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.

Indexed as

Biomarkers, TumorBreast NeoplasmsNeoplasm ProteinsNeoplasm Recurrence, LocalProteoglycansAdultAgedAnimalsCell Line, TumorFemaleHumansMiceMiddle AgedMucin-1Biomarkers, TumorESM1 protein, humanMucin-1Neoplasm ProteinsProteoglycansanimal modelsbiomarkerclinical studyEndocanrecurrence

Identifiers

PMID39331092
PMCPMC11495321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.